Mark J. Ratain to Animals
This is a "connection" page, showing publications Mark J. Ratain has written about Animals.
Connection Strength
0.228
-
Biomarkers in early cancer drug development: limited utility. Clin Pharmacol Ther. 2009 Feb; 85(2):134-5.
Score: 0.021
-
Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther. 2007 Oct; 82(4):381-8.
Score: 0.019
-
"Irinogenetics" and UGT1A: from genotypes to haplotypes. Clin Pharmacol Ther. 2004 Jun; 75(6):495-500.
Score: 0.015
-
Irinotecan treatment in cancer patients with UGT1A1 polymorphisms. Oncology (Williston Park). 2003 May; 17(5 Suppl 5):52-5.
Score: 0.014
-
Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors. Clin Cancer Res. 2002 Aug; 8(8):2519-23.
Score: 0.013
-
Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs. 2001 May; 19(2):171-7.
Score: 0.012
-
Gazing into a crystal ball-cancer therapy in the post-genomic era. Nat Med. 2001 Mar; 7(3):283-5.
Score: 0.012
-
5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy. Cancer Invest. 1999; 17(7):494-506.
Score: 0.010
-
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 1998 Feb 15; 101(4):847-54.
Score: 0.010
-
Clinical pharmacology of camptothecins. Cancer Chemother Pharmacol. 1998; 42 Suppl:S31-43.
Score: 0.010
-
Pharmacogenetics in cancer etiology and chemotherapy. Clin Cancer Res. 1997 Jul; 3(7):1025-30.
Score: 0.009
-
Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol. 1997; 39(5):440-4.
Score: 0.009
-
Promising new agents in oncologic treatment. Curr Opin Oncol. 1996 Nov; 8(6):525-34.
Score: 0.009
-
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clin Cancer Res. 2016 Oct 01; 22(19):4890-4900.
Score: 0.009
-
Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. Cancer Res. 1996 Mar 15; 56(6):1309-14.
Score: 0.009
-
Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter 1 via binding to an evolutionary conserved region in intron 1 of the OCT1 gene. J Pharmacol Exp Ther. 2013 Oct; 347(1):181-92.
Score: 0.007
-
Therapeutic relevance of pharmacokinetics and pharmacodynamics. Semin Oncol. 1992 Aug; 19(4 Suppl 11):8-13.
Score: 0.007
-
Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst. 2011 Aug 17; 103(16):1222-6.
Score: 0.006
-
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst. 2010 Nov 17; 102(22):1698-705.
Score: 0.006
-
Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial. J Natl Cancer Inst. 1988 Nov 02; 80(17):1412-6.
Score: 0.005
-
Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics. 2008 Apr 22; 33(2):278-91.
Score: 0.005
-
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther. 2007 Mar; 81(3):328-45.
Score: 0.005
-
Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemother Pharmacol. 2002 Apr; 49(4):336-41.
Score: 0.003
-
Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst. 1999 Aug 04; 91(15):1281-7.
Score: 0.003
-
Laboratory and clinical studies of biochemical modulation by hydroxyurea. Semin Oncol. 1992 Jun; 19(3 Suppl 9):84-9.
Score: 0.002